ASSESSMENT OF THE RELATIONSHIP OF THE RISK OF CARDIOVASCULAR DISEASES WITH ESTRADIOL LEVELS IN YOUNG AND MIDDLE-AGED MEN

Aim: To study the relationship between the risk of developing cardiovascular diseases and estradiol levels in young and middle-aged men. Material and methods: A retrospective clinical case-control study was conducted. 365 medical records of male patients aged 18 to 59 years were analyzed. The main group included 71 patients with newly diagnosed hyperestrogenism - HE (serum estradiol level > 41.2 pg/ml). Using pseudorandomization, 68 men with normal estradiol levels, comparable in age and body mass index (BWI) to the main group, were selected into the control group. In both groups, anthropometric data, bioimpedance measurements and blood pressure (BP) levels, levels of estradiol, testosterone, glucose and total cholesterol were analyzed. Results: Patients of the main and control groups did not differ in age, BWI and smoking. The testosterone level in the group with HE was 10.18 nmol/l, in the control group - 12.18 nmol/l (p=0.006). Systolic blood pressure in the group with HE was 142.0 mmHg. Art., in the control group - 135.2 mm Hg. Art. (p=0.011), diastolic blood pressure in the group with HE was 90.3, and in the control group - 86.2 mmHg. Art. (p=0.008). The level of total cholesterol in the blood in the group with HE was 5.87 mmol/l, in the control group - 5.33 mmol/l (p=0.023). Glucose levels did not differ between groups. The presence of HE in men in our sample increased the likelihood of developing arterial hypertension by 2.11 times (p = 0.038). The differences in SCORE between groups did not reach statistical significance (p=0.172). BWI, waist and hip circumference, and bioimpedance data on body composition did not differ between the patient groups. Conclusion: In the studied cohort of young and middle-aged men, HE was an independent predictor of the presence of arterial hypertension. There were no significant differences in assessing the total risk of developing cardiovascular diseases, calculated using the SCORE scale, between the patient groups.